Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1963 1
1964 2
1965 1
1967 2
1968 2
1969 5
1970 3
1974 1
1975 1
1982 1
1984 2
1985 5
1986 4
1987 1
1988 2
1989 2
1990 1
1991 1
1992 5
1993 4
1994 3
1995 1
1996 1
1997 3
1998 4
1999 2
2000 4
2001 5
2002 2
2003 5
2004 2
2005 5
2006 3
2007 7
2008 7
2009 8
2010 3
2011 11
2012 7
2013 12
2014 12
2015 14
2016 9
2017 13
2018 17
2019 12
2020 11
2021 25
2022 20
2023 12
2024 7

Text availability

Article attribute

Article type

Publication date

Search Results

262 results

Results by year

Filters applied: . Clear all
Page 1
Long-term benefits of dapagliflozin on renal outcomes of type 2 diabetes under routine care: a comparative effectiveness study on propensity score matched cohorts at low renal risk.
Fadini GP, Longato E, Morieri ML, Del Prato S, Avogaro A, Solini A; DARWIN-Renal Study Investigators. Fadini GP, et al. Among authors: solini a. Lancet Reg Health Eur. 2024 Feb 1;38:100847. doi: 10.1016/j.lanepe.2024.100847. eCollection 2024 Mar. Lancet Reg Health Eur. 2024. PMID: 38328413 Free PMC article.
Extra-glycaemic properties of empagliflozin.
Solini A. Solini A. Diabetes Metab Res Rev. 2016 Mar;32(3):230-7. doi: 10.1002/dmrr.2666. Epub 2015 Jun 25. Diabetes Metab Res Rev. 2016. PMID: 25994513 Review.
Editorial: Endocrine and metabolic diseases.
Solini A. Solini A. Curr Opin Pharmacol. 2020 Dec;55:vii-ix. doi: 10.1016/j.coph.2020.12.005. Curr Opin Pharmacol. 2020. PMID: 33357461 No abstract available.
Clinical Features, Cardiovascular Risk Profile, and Therapeutic Trajectories of Patients with Type 2 Diabetes Candidate for Oral Semaglutide Therapy in the Italian Specialist Care.
Morieri ML, Candido R, Frontoni S, Disoteo O, Solini A, Fadini GP; PIONEERING EXPERIENCE study group. Morieri ML, et al. Among authors: solini a. Diabetes Ther. 2023 Dec;14(12):2159-2172. doi: 10.1007/s13300-023-01490-6. Epub 2023 Oct 18. Diabetes Ther. 2023. PMID: 37848758 Free PMC article.
Canagliflozin on top of dual renin-angiotensin system blockade in a woman with partial acquired lipodystrophy, type 2 diabetes and severely proteinuric chronic kidney disease: a case report.
Biancalana E, Ceccarini G, Magno S, Ortenzi V, Giannese D, Santini F, Solini A. Biancalana E, et al. Among authors: solini a. Front Endocrinol (Lausanne). 2023 May 19;14:1172468. doi: 10.3389/fendo.2023.1172468. eCollection 2023. Front Endocrinol (Lausanne). 2023. PMID: 37274321 Free PMC article.
262 results